All‐cause mortality · patients with chronic obstructive pulmonary disease
Self‐management interventions showed no clear difference in all‐cause mortality compared with usual care (low certainty).
Mortality (all‐cause) · stable COPD
Triple therapy may leads to lower mortality (all‐cause) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
All‐cause mortality · adults with central sleep apnoea associated with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults with central sleep apnoea associated with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults with primary central sleep apnoea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults with central sleep apnoea associated with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
All‐cause mortality
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Mortality (all‐cause) · adults with chronic bronchitis or chronic obstructive pulmonary disease
Summary of findings table ‐ immunostimulant showed no clear difference in mortality (all‐cause) compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1 vaccination
Inhaled corticosteroids plus standard care showed no clear difference in all‐cause mortality compared with standard care (with or without placebo) (low certainty).
1 finding from 1 review
All‐cause mortality · post‐exacerbation COPD
Summary of Findings Table ‐ Chronic non‐invasive ventilation showed no clear difference in all‐cause mortality compared with standard treatment following a severe exacerbation (low certainty).
1 finding from 1 review
All‐cause mortality · stable COPD
Summary of Findings Table ‐ Chronic non‐invasive ventilation probably leads to lower all‐cause mortality compared with standard treatment (moderate certainty).
1 finding from 1 review
All‐cause mortality · children with chronic asthma
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
It is very uncertain whether remote monitoring plus usual care changes mortality (all‐cause) compared with usual care (very low certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
It is very uncertain whether remote monitoring changes mortality (all‐cause) compared with usual care (very low certainty).
1 finding from 1 review
All‐cause mortality · COPD and at least one other long‐term condition
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in all‐cause mortality compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
All‐cause mortality · children and adolescents with chronic asthma
1 finding from 1 review
All‐cause mortality · Adults with COPD
Statins showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review